Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alger Spectra Fund Patrick Kelly, Dan Chung, Ankur Crawford | “Cidara Therapeutics is a biotechnology company developing drug-Fc conjugate therapeutics, with its lead program CD388 designed to prevent influenza infection in high-risk populations. CD388 advanced into the Phase 3 ANCHOR study following compelling Phase 2b NAVIGATE results. The program is positioned as a potentially first-in-class, single-dose prophylactic option for influenza prevention. Shares contributed positively after Merck announced an all-cash agreement to acquire Cidara for approximately $9.2 billion. BSD Analysis: Cidara is a clinical-stage biotech focused on long-acting antiviral and antifungal therapies using its Cloudbreak platform. The strategy is to replace chronic dosing with single or infrequent administrations. This approach could materially improve adherence and outcomes in vulnerable patient populations. Clinical data remains early, making valuation highly sensitive to trial results. Partnerships help offset funding risk, but dilution remains a reality. If efficacy is validated, the commercial potential is significant. This is a high-risk, science-driven optionality play.” | BULL | Q4 2025 Jan 8, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
